A comprehensive guide to monitoring, preventing, and managing the acute and long-term side effects of peptide receptor radionuclide therapy (PRRT) with lutetium-177 DOTATATE in neuroendocrine tumor patients.
Multi-organ toxicities across 3 timeframesPRRT can cause acute, subacute, and long-term side effects affecting blood cells, kidneys, and other systems, requiring systematic monitoring and prevention strategies
What the researchers found
This review provides a comprehensive guide to managing the toxicities of peptide receptor radionuclide therapy (PRRT) with lutetium-177 DOTATATE in neuroendocrine tumor patients. Toxicities can be acute, subacute, or long-term, affecting multiple organ systems. Key management topics include screening for clonal hematopoiesis before treatment (a risk factor for blood cancers), steroid prophylaxis to prevent carcinoid crisis and bowel obstruction, and evidence-based monitoring strategies for kidney and bone marrow toxicity.
Why it matters
As PRRT use grows with rising neuroendocrine tumor incidence, more clinicians need practical guidance on managing its side effects. This review consolidates current evidence on toxicity management into a single resource, addressing emerging concerns like pre-treatment clonal hematopoiesis screening that could prevent rare but serious blood cancers.
The numbers in context
Key trials referenced: NETTER-1 and NETTER-2 · Agent: lutetium-177 DOTATATE · Toxicity timeframes: acute, subacute, long-term
How the study worked
Narrative review of published literature on PRRT toxicities, summarizing evidence from clinical trials (NETTER-1, NETTER-2) and clinical experience with monitoring, prevention, and management strategies.
Who was studied
Patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) expressing somatostatin receptors, treated with PRRT
What this study cannot tell us
Narrative review without systematic search methodology or meta-analysis. Management recommendations are based on available evidence and clinical experience, which may be limited for rare toxicities. The rapidly evolving nature of PRRT practice means some recommendations may change quickly.
How to read the evidence
This is a narrative review synthesizing evidence from landmark clinical trials (NETTER-1, NETTER-2) and clinical practice. While not a systematic review, it provides a practical evidence-based framework for toxicity management from experienced clinicians in the field.
When this study was published
Published in 2026, this is a current review reflecting the latest evidence and emerging practices in PRRT management, including the new paradigm of clonal hematopoiesis screening.
The bigger picture
PRRT represents one of the most successful applications of peptide-based targeted therapy — using somatostatin analog peptides as guided missiles to deliver radiation to tumors. As it moves from specialized centers to broader oncology practice, standardizing toxicity management becomes critical. This review also reflects the growing recognition that pre-treatment genomic screening (for clonal hematopoiesis) may help identify patients at higher risk for therapy-related blood cancers.
Questions still open
- Should clonal hematopoiesis screening become mandatory before all PRRT treatments, and what thresholds warrant treatment modification?
- As newer radiolabeled peptides enter clinical trials, will their toxicity profiles differ from lutetium-177 DOTATATE?
- Can optimized dosing schedules or renal protective agents reduce long-term kidney toxicity from PRRT?
Common questions
What is peptide receptor radionuclide therapy (PRRT)?
What are the most serious side effects of PRRT?
Read the original research
Management of Peptide Receptor Radionuclide Therapy Toxicities in Neuroendocrine Neoplasm Patients.
Current treatment options in oncology, 27(1), 6
Citation
Mohindroo, Chirayu; Ramirez, Robert A. (2026). Management of Peptide Receptor Radionuclide Therapy Toxicities in Neuroendocrine Neoplasm Patients.. Current treatment options in oncology, 27(1), 6. https://doi.org/10.1007/s11864-026-01379-z